Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT05318469 trial: what clinicians have said so far
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
- NCT05318469 ↗
- Recruiting
- Yuan Yuan
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05318469 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05318469 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; HR+ / HER2- Advanced Breast Cancer
- Interventions
- Ivermectin; Balstilmab; Pembrolizumab
- Arms
- Treatment (ivermectin, balstilimab) · Experimental
- Enrollment
- 34 (estimated)
- Primary outcomes
- Incidence of adverse events
- Objective response rate
- Sponsor
- Yuan Yuan with Agenus Inc., Gateway for Cancer Research
- Start
- Oct 13, 2023
- Primary completion
- Oct 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05318469 · updated Oct 30, 2026